Prothena Stock Price

0.54 (2.33%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Prothena Corporation PLC PRTA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.54 2.33% 23.76 16:01:00
Open Price Low Price High Price Close Price Prev Close
23.13 22.56 24.34 23.76 23.22
Bid Price Ask Price Spread News
20.00 24.39 4.39 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,059 128,410 $ 23.82 $ 3,058,893 247,426 6.44 - 28.6599
Last Trade Time Type Quantity Stock Price Currency
16:08:08 priorref 165 $ 23.76 USD

Prothena Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 948.53M 39.92M 30.48M $ 814.00k $ - -1.95 -5.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Prothena News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PRTA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week24.2325.9622.0224.18210,256-0.47-1.94%
1 Month24.881728.659921.5525.00357,329-1.12-4.51%
3 Months12.3528.659910.7221.50527,27911.4192.39%
6 Months12.2528.659910.7218.29375,47711.5193.96%
1 Year9.7428.65996.4415.24329,39914.02143.94%
3 Years13.6928.65996.4413.17363,51610.0773.56%
5 Years47.7070.006.4427.14361,636-23.94-50.19%

Prothena Description

Prothena Corp PLC is a biotechnology company focuses on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.